Quick answer
The Wolverine Stack is BPC-157 10 mg + TB-500 10 mg (20 mg, 1 : 1 by mass); the Glow Stack is the same two peptides plus 50 mg GHK-Cu (70 mg, 5 : 1 : 1). Moving from one to the other adds a copper(II) tripeptide complex that dominates the vial by mass and by moles, colors the solution blue, and brings copper-specific handling limits (no phosphate, chelators or reducing agents). The choice depends on the question: a two-peptide tissue-response or migration design fits the Wolverine, while a design that includes matrix-remodeling readouts relevant to GHK-Cu fits the Glow. Neither has been tested as a blend in the studies reviewed. For laboratory research use only; not for human consumption.
The two blends are easy to confuse because they overlap. They share BPC-157 and TB-500 in equal mass, and one carries a third peptide. That one addition changes more than the label. This comparison sets out, from the product pages and the primary literature, what differs in composition, in molar terms, in chemistry and handling, and in experimental design. It is a comparison of laboratory materials and makes no claims about effects in people. The two products are the Glow Stack and the Wolverine Stack; a broader three-way view that also includes the KLOW stack is in Glow vs KLOW vs Wolverine.
Composition side by side
| Property | Wolverine Stack | Glow Stack |
|---|---|---|
| Components | BPC-157 + TB-500 | GHK-Cu + BPC-157 + TB-500 |
| Label masses | 10 mg + 10 mg | 50 mg + 10 mg + 10 mg |
| Total per vial | 20 mg | 70 mg |
| Mass ratio | 1 : 1 | 5 : 1 : 1 (GHK-Cu first) |
| Purity | ≥98% by HPLC | ≥98% by HPLC |
| Appearance | Colorless solution expected | Blue cake and blue solution (copper complex) |
| Storage | 2–8 °C; −20 °C long-term; protect from heat, moisture, light | Same storage line |
| Documented lot (product page) | ARC-WV10-004 | ARC-GL70-002 |
The shared storage line hides a difference in what can go wrong, covered below. Facts in this table are taken from the product pages.
Molar view: how different the vials really are
Mass ratios understate the difference because the three peptides differ in size. GHK-Cu (about 404 g/mol as the complex) is small, so 50 mg is a large number of molecules, whereas BPC-157 (about 1,419.5 g/mol) is large.
| Component | Molecular weight (approx.) | In Wolverine vial | In Glow vial |
|---|---|---|---|
| BPC-157 | 1,419.5 g/mol | 10 mg, about 7.0 µmol | 10 mg, about 7.0 µmol |
| TB-500 (7-residue fragment, if that is the identity) | about 889 g/mol | 10 mg, about 11.2 µmol | 10 mg, about 11.2 µmol |
| GHK-Cu | about 404 g/mol | None | 50 mg, about 124 µmol |
| BPC-157 : TB-500 molar ratio | — | about 1 : 1.6 | about 1 : 1.6 |
The molar ratio between BPC-157 and TB-500 is identical in the two vials; only the GHK-Cu changes. In the Glow vial GHK-Cu accounts for roughly 87% of the moles of peptide. Figures assume 100% peptide content and the standard weights, and should be recalculated from certificate values, especially for TB-500, whose identity is stated on the certificate and not on the product page. The conversion arithmetic is explained in the reconstitution calculator guide.
What the literature says about the shared pair
The two blends share their research basis for BPC-157 and TB-500. BPC-157 in tendon explants accelerated outgrowth and promoted migration and survival, with increased FAK and paxillin phosphorylation (Chang and colleagues, 2011), and in angiogenesis models it raised vessel density and VEGFR2 expression (Hsieh and colleagues, 2017). Full-length thymosin beta-4 increased re-epithelialization and angiogenesis in rat wounds and stimulated keratinocyte migration (Malinda and colleagues, 1999); an actin-binding fragment promoted repair in aged mice (Philp and colleagues, 2003). Both blends therefore suit questions about migration, angiogenic readouts and tissue response, and the Wolverine is the cleaner choice when the aim is to study only those two peptides together. The pair itself is discussed in BPC-157 and TB-500 combination research.
What GHK-Cu adds to the literature basis
GHK-Cu brings a different set of readouts. It stimulated collagen synthesis in fibroblast cultures across a wide concentration range (Maquart and colleagues, 1988), affected MMP-2 and TIMP release in a way that copper ions alone reproduced for MMP-2 (Siméon and colleagues, 2000), and in a rat ischemic wound model was associated with greater reduction in wound area and lower tissue TNF-alpha, MMP-2 and MMP-9 than no exposure (Canapp and colleagues, 2003). A study whose endpoints are matrix production or remodeling therefore has a reason to include GHK-Cu, and a study without such endpoints does not. The compound is described further in the GHK-Cu overview.
Handling differences caused by copper
| Handling point | Wolverine Stack | Glow Stack |
|---|---|---|
| Diluent | Water or preserved diluent; usual peptide considerations | Chelator-free, phosphate-free diluent; copper can precipitate in phosphate or be stripped by chelators |
| Reducing agents | Not a specific concern for the blend as sold | Can reduce Cu(II) and change the species under study |
| Visual check | Clear, colorless, no particles | Clear, uniformly blue, no particles; loss of blue is a warning |
| Light | Standard precaution | Product page notes copper peptides are light-sensitive in solution |
| Concentrations to track | Two (equal in mg/mL) | Three (GHK-Cu five times each of the others in mg/mL) |
| Aliquots | Recommended for multi-day work | Recommended; keep dark and cold |
The practical rule is that the Glow Stack asks for a stricter diluent policy. Background chemistry is in the article on GHK-Cu and the stock-preparation steps are in the GLOW reconstitution and storage guide and BPC-157 + TB-500 blend reconstitution.
Concentration examples
Following the product pages' arithmetic (component mass divided by diluent volume), a 2 mL fill gives 5 mg/mL of each peptide in the Wolverine vial (10 mg/mL total), and 25 mg/mL GHK-Cu with 5 mg/mL each of the other two in the Glow vial (35 mg/mL total). A 4 mL fill gives 2.5 mg/mL of each peptide in the Wolverine and 12.5, 2.5 and 2.5 mg/mL in the Glow. The BPC-157 and TB-500 concentrations are the same in both vials at the same volume, so a lab can run a Wolverine arm and a Glow arm at matched BPC-157 and TB-500 and attribute any difference to GHK-Cu. The calculator returns other volumes.
Choosing between them, by research question
| Research question | Better fit | Reason |
|---|---|---|
| Cell migration or angiogenic readout with BPC-157 and TB-500 only | Wolverine Stack | Two components; fewer variables; no copper chemistry |
| Matrix, collagen or MMP/TIMP readouts in dermal cells | Glow Stack, plus single-agent arms | GHK-Cu is the component with that literature |
| Does adding GHK-Cu change the effect of the pair? | Both, side by side | Matched BPC-157 and TB-500 in both arms isolates the GHK-Cu contribution |
| Concentration–response for one peptide | Neither; use single-agent vials | A blend cannot supply the single-agent curve |
| Fixed-ratio combination screen | Whichever matches the intended ratio | Ratios are fixed at 1 : 1 and 5 : 1 : 1 by mass |
Single-agent vials remain necessary for any rigorous claim, which is the point of the design discussion in Glow Stack vs individual peptides.
A matched-arm experiment using both vials
Because the two vials hold identical BPC-157 and TB-500 content, they make a convenient pair for a controlled comparison. The idea is to reconstitute both to the same BPC-157 and TB-500 concentrations and to use the Wolverine arm as the reference for everything except GHK-Cu.
- Arm 1: vehicle. Diluent only, at the same volume fraction as the other arms.
- Arm 2: Wolverine. BPC-157 and TB-500 at the chosen working concentration.
- Arm 3: Glow. The same working concentrations of BPC-157 and TB-500, with GHK-Cu present at five times the mass concentration.
- Arm 4: GHK-Cu alone. At the GHK-Cu concentration delivered in arm 3, from a single-agent vial.
- Arm 5: copper salt. At the copper concentration delivered in arm 3, to separate metal from peptide effects.
The logic is subtractive. A difference between arms 2 and 3 points to GHK-Cu or to the copper it carries, and arms 4 and 5 test which. If arm 3 differs from the sum predicted from arms 2 and 4 by more than experimental variability, an interaction is suggested, and the formal analysis methods are described in the companion article on testing synergy for the Glow Stack. The design still depends on the usual safeguards: independent replicates, a pre-declared readout and time point, freshly diluted stocks and a record of each lot and its certificate. It also depends on a diluent that is compatible with copper, since a phosphate buffer that clouds only the Glow arm would create a difference that has nothing to do with biology.
Documentation to compare before ordering
A short list of questions applies to either vial and to any other blend. Does the certificate identify each component separately? Is purity reported per component or only as one figure? Is the mass of each peptide confirmed, and does the TB-500 identity match the paper you intend to rely on? Is the lot number on the certificate the one on the label? The reasoning behind each question is set out in how to read a COA and understanding HPLC purity, and the quality checklist for the Glow Stack applies almost unchanged to the Wolverine Stack, minus the copper checks.
What neither blend has been tested for
No peer-reviewed study in the sources reviewed tested either blend as a single test article, and no cited paper used the 1 : 1 or 5 : 1 : 1 ratios. All the evidence above comes from single compounds in cells and animals. Any claim that one blend outperforms the other has no support in the reviewed literature. Documentation, where published, is on the COA page, and reading it is covered in how to read a COA.
Related reading
- Glow vs KLOW vs Wolverine stack
- GLOW peptide blend overview
- BPC-157 and TB-500 combination research
- BPC-157 + TB-500 blend reconstitution
- Where to buy the Glow Stack for research
- Research peptide catalog
Frequently asked questions
What is the difference between the Glow Stack and the Wolverine Stack?
Both contain BPC-157 (10 mg) and TB-500 (10 mg). The Glow Stack adds 50 mg of GHK-Cu, making 70 mg total at a 5:1:1 mass ratio, whereas the Wolverine is 20 mg total at 1:1.
Do the two blends have the same BPC-157 and TB-500 content?
Yes. Each vial holds 10 mg of each, so at the same diluent volume their concentrations of those two peptides match.
Why is the Glow Stack blue?
The copper(II) complex in GHK-Cu gives the cake and the solution a blue color. The Wolverine Stack has no copper and is expected to be colorless.
Which blend needs more careful diluent choice?
The Glow Stack, because copper can precipitate in phosphate or be stripped by chelators, and reducing agents can change the complex.
Can I attribute a difference between the two blends to GHK-Cu?
If BPC-157 and TB-500 concentrations are matched, a difference between the arms is attributable to the added GHK-Cu in that system, subject to proper replication and a vehicle control.
Has either blend been tested in a published study?
Not in the sources reviewed. The published work tests the single compounds.
Are these intended for use in people?
No. Both are supplied for laboratory research use only, and the studies cited describe cells and animals.
Related reading: Glow Stack Skin Repair and Anti-Aging Research Evidence, Glow Stack Quality Checklist: COA and Receiving Inspection, Glow Stack Research Guide: Component Reference Sheet.
References
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010
- Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al.. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
- Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, et al.. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. doi:10.1046/j.1523-1747.1999.00708.x
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. doi:10.1046/j.1524-475x.2003.11105.x
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. doi:10.1016/0014-5793(88)80509-x
- Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. doi:10.1016/s0024-3205(00)00803-1
- Canapp SO Jr, Farese JP, Schultz GS, Gowda S, Ishak AM, Swaim SF, et al.. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-23. doi:10.1111/j.1532-950x.2003.00515.x
